Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer

3 of 4 episodes

Details

Episodes

Presenters

Overview
Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.

The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.

Faculty:
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Division of Hematology/Oncology
David Geffen School of Medicine, UCLA
Los Angeles, CA
Research: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, OnKure, Pfizer
Consulting Fees: Alyssum, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome
Erica L. Mayer, MD, MPH
Senior Physician
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Consulting Fees: Arvinas, AstraZeneca, Eli Lilly, Novartis
Reviewers/Planners/Authors:
- Sandra Hannaford has no relevant relationships to disclose.
- Cristen Query has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Evaluate emerging data on endocrine pathway-targeted and precision therapies in early-stage and metastatic breast cancer (MBC), considering trial design, patient eligibility, efficacy, and safety
- Apply newly presented evidence on oral targeted agents in breast cancer to optimize patient selection, treatment sequencing, and real-world management across community and academic practice settings
Target Audience
This activity has been designed to meet the educational needs of medical oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with breast cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Global Learning Collaborative designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative designates this activity for 0.50 contact hour(s)/0.05 CEUs of pharmacy contact hour(s).

The Universal Activity Number for this program is JA0006235-0000-26-069-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

Global Learning Collaborative has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 05/06/2027. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)

Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from Stemline Therapeutics, Inc., and AstraZeneca.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/04/2026
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.